Santhera Pharmaceuticals Holding AG (SWX:SANN)

Market Cap	212.00M +22.7%
Revenue (ttm)	77.19M +97.3%
Net Income	-49.24M
EPS	-3.78
Shares Out	13.95M
PE Ratio	n/a
Forward PE	168.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,687
Open	15.84
Previous Close	15.80
Day's Range	15.08 - 15.84
52-Week Range	9.38 - 18.84
Beta	-0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 23, 2026

About SWX:SANN

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 94
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: SANN

Financial Performance

In 2025, SWX:SANN's revenue was 77.19 million, an increase of 97.32% compared to the previous year's 39.12 million. Losses were -49.24 million, 17.3% more than in 2024.